intravenous glutathione randomized controlled trial parkinson's disease Frontiers The glutathione system in Parkinson's
Description
doi:10.1128/JB.187.17.5901-5909.2005
doi: 10.1177/08853282221076708
doi: 10.1515/revneuro-2013-0034 25
Once purified, antibodies were analyzed via non-reducing SDS-PAGE, isoelectric focusing, Lab-on chip Agilent 2100, and ELISA in order to identify patterns which could serve as guidelines for determining their pathogenic potential in lupus
The chromatographic separation was as previously described [20]
This excellent safety record contributed to the peptides characterization as having tolerability indistinguishable from placebo in published research
